While the need for prospective trials dominates the ctDNA discussion, a more fundamental obstacle is the lack of standardization between assay types (e.g., tumor-informed vs. agnostic). Without a common measurement approach, data from disparate trials cannot be pooled to create a universally accepted surrogate endpoint for regulatory approval.

Despite emerging trial data, clinicians are not yet ready to change therapy based on ctDNA positivity alone. Key concerns cited include the absence of a proven survival benefit from early intervention, the potential to use future treatment lines prematurely, and overall feasibility. The consensus is that while promising, the technology is not yet ready for routine clinical decision-making.

Historically, discussing adjuvant therapy for Stage III colon cancer was quick and straightforward, while Stage II was complex. The advent of ctDNA testing has reversed this dynamic. Stage II decisions are now clearer (treat if positive), while Stage III discussions have become much longer and more nuanced as clinicians integrate ctDNA data with patient preferences.

While ctDNA can detect molecular relapse 3-5 months before radiographic progression, experts argue this lead time is too short and doesn't sufficiently alter management to justify routine use outside of trials. The lack of superior subsequent therapies currently limits its clinical actionability and value.

Establishing a multi-disciplinary molecular tumour board helps operationalize biomarker strategies. This collaborative body, including oncologists and surgeons, not only interprets complex molecular data for trial matching but also collectively advocates for health insurance reimbursement for necessary tests, addressing a key practical barrier.

The FDA is predicted to approve new PARP inhibitors from trials like AMPLITUDE only for BRCA-mutated patients, restricting use to where data is strongest. This contrasts with the EMA's potential for broader approvals or denials. This highlights the diverging regulatory philosophies that create different drug access landscapes in the US and Europe.

Advanced diagnostics like Signatera ctDNA and therapies such as adjuvant nivolumab, while becoming standard in the US, are often unavailable in Europe and elsewhere. This creates a significant gap in care, making many cutting-edge discussions purely theoretical for a large portion of the world's oncologists and patients.

Groundbreaking trials demonstrating ctDNA's power in bladder cancer almost exclusively used tumor-informed "bespoke" assays like Signatera. This is a critical distinction, as the results may not translate to more common, non-bespoke ctDNA testing methods used in clinical practice.

The main barrier to widespread ctDNA use is not its proven ability to predict who will recur (prognostic value). The challenge is the emerging, but not yet definitive, data on its ability to predict a patient's response to a specific therapy (predictive value).